BD’s microinjection system receives approval

BD’s microinjection system used in an intradermal influenza vaccine has been given marketing authorisation by the European Commission.

The company said its Soluvia product, which is part of sanofi pasteur’s Intanza or IDflu solution, is easy to use and offers a proven and reliable intradermal delivery method.

A 1.5 mm BD microneedle is combined with 0.1 ml of injected volume, delivering the vaccine to the dermal skin layer instead of the muscle.

BD said this not only provides efficient and direct access to the patient’s immune system but also reduced risk and an increased level of sterility.

Vice-president of medical affairs at BD Medical Pharmaceutical Systems Phillipe Laurent said the group was “pleased” to be involved with the first flu vaccine delivered intradermally.

“The minimally invasive BD Soluvia microinjection system has the potential to increase patient participation in immunisation programs,” he added.

Other products manufactured by BD include prefillable drug delivery systems, syringes and pen needles for insulin injection and critical car monitoring devices.